We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates.

Stanford Medicine researchers have built CRISPR-GPT, a large language model designed to automate the full arc of gene-editing ...

Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the future of gene editing.

The powerful gene-editing technique CRISPR–Cas9 might offer a way to make safer, more effective cancer-fighting immune cells engineered inside the human body, a mouse study has found. Cancer-fighting ...

Earlier in March 2026, CRISPR Therapeutics completed a US$550 million private offering of 1.7308% Convertible Senior Unsecured Notes due March 1, 2031, issued under Rule 144A to bolster its funding ...

A vanadium MXene nanoparticle uses gene editing to strip tumors of heat resistance, then kills them with laser-triggered free ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $46.93, demonstrating a -1.59% change from the preceding day's closing price. This change lagged the S&P 500's 0.28% loss on the day.

Crispr Therapeutics Ag (NASDAQ:CRSP) is one of the Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Biotech company Crispr ...

CRISPR Therapeutics (NASDAQ:CRSP) has had a rough stretch lately. Shares have dropped 5% over the past week and are down 8% year-to-date, trading around $49.37 as of Tuesday morning. Piper Sandler, ...

UCSF scientists found a precise way to turn on cancer-fighting immune cells inside the body. This more potent form of CAR-T has the potential to treat many more cancers.

After a heart attack, the heart struggles to recoup and maintain energy. One-third of patients develop heart failure as a ...

Current shareholders were thrown an unexpected curveball that they actually should have been expecting.